|Bid||20.01 x 800|
|Ask||20.06 x 1300|
|Day's range||19.80 - 20.24|
|52-week range||15.72 - 31.54|
|Beta (5Y monthly)||1.42|
|PE ratio (TTM)||N/A|
|Earnings date||06 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||32.80|
Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.